Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUVED + REIMMUGEN
- Development stage
- Phase 3
- Lead developer
- SUPRA Health Solutions
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
SUVED + REIMMUGEN is an integrative Ayurvedic combination therapy developed by SUPRA Health Solutions LLP for the treatment of various vascular diseases, including coronary artery disease (CAD), cardiovascular disease (CVD), stroke (CVA), deep vein thrombosis (DVT), and peripheral arterial disease (PAD). SUVED is a polyherbal extract (ghana) formulation containing herbs such as Terminalia arjuna, Withania somnifera, and Terminalia chebula, which are traditionally used for their cardiotonic, antioxidant, and potential clot-dissolving properties. REIMMUGEN consists of whole bovine colostrum, which is rich in immunoglobulins (IgA, IgG, IgM, IgE, IgD), growth factors (including vascular endothelial growth factor and epidermal growth factor), and lactoferrin. This combination is intended to enhance immunity, support endothelial repair, and provide cardioprotective effects when administered alongside conventional medical therapies. It has been evaluated in double-blind, placebo-controlled clinical trials in India for vascular conditions and COVID-19.
- Other names
- SUVED + REIMMUGEN Colostrum
02
Targets
LTF (Lactoferrin)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on SUVED + REIMMUGEN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUVED + REIMMUGEN.